DREAMM‑3 - Blenrep (Belmaf) Vs PomDex For Relapsed/Refractory Myeloma | Katja Weisel, MD | ASCO 2023

DREAMM-3: belantamab mafodotin vs pom/dex for R/R myelomaПодробнее

Dreamm-3 and belantamab mafodotin, a new myeloma drugПодробнее

CAR-T Cell Therapy Cilta-cel for Relapsed/Refractory Myeloma | Doris Hansen, MD | ASCO 2023Подробнее

Dreamm-3 and belantamab mafodotin, a new myeloma drug (German)Подробнее

DREAMM-3: safety of belantamab mafodotin versus pom/dex in patients with R/R myelomaПодробнее

DREAMM-7: Belamaf+BVd vs DVd in RRMM, analyses of phase 3 trial comparing regimens after relapseПодробнее

Phase 3, open-label, randomized trial comparing belamaf to Pd in RRMM: DREAMM-3 studyПодробнее

OPTIMISMM: PVd for lenalidomide-refractory myelomaПодробнее

Final analysis of the DREAMM-2 trial: belantamab mafodotin for R/R multiple myelomaПодробнее

DREAMM-9: Phase III study belantamab mafodotin plus VRd vs VRd alone in transplant-ineligible NDMMПодробнее

DREAMM-6: Safety and tolerability of belantamab mafodotin in combination with bortezomib/dex in RRMMПодробнее

BLENREP (belantamab mafodotin-blmf) Mechanism of Action in Multiple MyelomaПодробнее

Efficacy and Safety of Elranatamab in Pts with Relapsed/Refractory Multiple Myeloma: MagnetisMM-3Подробнее

MagnetisMM-3: elranatamab in relapsed/refractory multiple myelomaПодробнее

Phase III ASPIRE study of carfilzomib, lenalidomide and dexamethasone in relapsed myelomaПодробнее

DREAMM-8: Belantamab mafodotin + pomalidomide and dex shows improved outcomes in RR multiple myelomaПодробнее

Evaluating Teclistamab in Relapsed and/or Refractory Multiple MyelomaПодробнее

Optimal usage of carfilzomib and pomalidomide in treating relapsed/refractory myelomaПодробнее